Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor.

Bicyclams represent a novel class of selective anti-HIV inhibitors with potent activity against T-cell tropic strains of HIV. The prototype compound, the bicyclam AMD3100, has an EC50 of 1 to 10 ng/ml against different strains of HIV-1, including clinical isolates. AMD3100 was shown to interact with the CXC-chemokine receptor CXCR4, the main coreceptor used by T-cell tropic strains of HIV. Here we describe the interaction of different bicyclam derivatives with CXCR4. A close correlation (r2 = 0.7) was found between the anti-HIV potency of the bicyclams and their ability to inhibit the binding of an anti-CXCR4 monoclonal antibody or the intracellular Ca++ signal induced by the stromal cell-derived factor-1alpha, the natural ligand of CXCR4. These results indicate that the mechanism of action of bicyclams is primarily mediated by their interaction with CXCR4. The most potent interaction with CXCR4 and thus anti-HIV activity was shown by bicyclam analogs with cyclam rings composed of fourteen members that are linked by an aromatic (phenyl) bridge. Elucidating the structural requirements for receptor interaction and the site(s) of interaction of bicyclams with CXCR4 will aid in the understanding of HIV-cell fusion.

[1]  E. De Clercq,et al.  The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication , 1996, Journal of virology.

[2]  J. Moore,et al.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.

[3]  J. Cohen.  Exploiting the HIV-Chemokine Nexus , 1997, Science.

[4]  E. Clercq.  Human immunodeficiency virus inhibitors targeted at virus-cell fusion and/or viral uncoating , 1992 .

[5]  W. O'brien,et al.  Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions , 1996, Journal of virology.

[6]  E. De Clercq,et al.  Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo. , 1999, The Journal of clinical investigation.

[7]  A. Sylwester,et al.  Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency , 1998, Nature Medicine.

[8]  Kouji Matsushima,et al.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.

[9]  Masahiko Kuroda,et al.  Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.

[10]  E. De Clercq,et al.  Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. , 1995, Journal of medicinal chemistry.

[11]  M. L. Penn,et al.  CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Baggiolini,et al.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.

[13]  S. Nisole,et al.  The V3 loop-mimicking pseudopeptide 5[Kpsi(CH2N)PR]-TASP inhibits HIV infection in primary macrophage cultures. , 1999, AIDS research and human retroviruses.

[14]  E. De Clercq,et al.  Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  E. De Clercq,et al.  Synthesis and Structure−Activity Relationships of Phenylenebis(methylene)- Linked Bis-tetraazamacrocycles That Inhibit Human Immunodeficiency Virus Replication. 2. Effect of Heteroaromatic Linkers on the Activity of Bicyclams , 1996 .

[16]  H. Buc,et al.  HIV-1 reverse transcription. A termination step at the center of the genome. , 1994, Journal of molecular biology.

[17]  A. Otaka,et al.  An anti-HIV peptide, T22, forms a highly active complex with Zn(II). , 1996, Biochemical and biophysical research communications.

[18]  H. Gendelman,et al.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.

[19]  I. De Clercq,et al.  The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. , 1996, Antiviral research.

[20]  O. Nishimura,et al.  A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. McCune,et al.  Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry , 1996, Antimicrobial agents and chemotherapy.

[22]  村上 努.  A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection , 1998 .

[23]  D. Markovitz,et al.  The role of mononuclear phagocytes in HTLV-III/LAV infection. , 1986, Science.

[24]  E. De Clercq,et al.  Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). , 1998, Molecular pharmacology.

[25]  A. Litovchick,et al.  Arginine‐aminoglycoside conjugates that bind to HIV transactivation responsive element RNA in vitro , 1999, FEBS letters.

[26]  J. Goudsmit,et al.  Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity , 1992, Journal of virology.

[27]  E. De Clercq,et al.  Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. , 1996, Antiviral research.

[28]  M. Baba,et al.  T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure , 1999, Journal of Virology.

[29]  R. Warnke,et al.  Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. , 1984, Cancer research.

[30]  P. Luciw,et al.  Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection , 1997, Journal of virology.

[31]  J J Goedert,et al.  Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) , 1998, Science.

[32]  B. Korber,et al.  A new classification for HIV-1 , 1998, Nature.

[33]  B Dewald,et al.  Human chemokines: an update. , 1997, Annual review of immunology.

[34]  P. Herdewijn,et al.  Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties. , 1997, Biochemistry.

[35]  E. De Clercq,et al.  Inhibition of HIV type 1 Tat-mediated trans-activation by oncostatin M in HLtat cells. , 1995, AIDS research and human retroviruses.

[36]  E. De Clercq,et al.  T-Cell-Line-Tropic Human Immunodeficiency Virus Type 1 That Is Made Resistant to Stromal Cell-Derived Factor 1α Contains Mutations in the Envelope gp120 but Does Not Show a Switch in Coreceptor Use , 1998, Journal of Virology.

[37]  E. De Clercq,et al.  Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. , 1997, Molecular pharmacology.

[38]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[39]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[40]  Anthony S. Fauci,et al.  Host factors and the pathogenesis of HIV-induced disease , 1996, Nature.

[41]  E. Dam,et al.  Identification of V3 Loop-binding Proteins as Potential Receptors Implicated in the Binding of HIV Particles to CD4+Cells* , 1998, The Journal of Biological Chemistry.

[42]  N. Heveker,et al.  Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity , 1997, Journal of virology.

[43]  E. Clercq,et al.  Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.

[44]  E. De Clercq,et al.  Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. , 1997, Antiviral research.

[45]  E. De Clercq,et al.  Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4 , 1999, Journal of Virology.

[46]  R. Doms,et al.  A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor , 1997, The Journal of experimental medicine.

[47]  A. Litovchick,et al.  Aminoglycoside-arginine conjugates that bind TAR RNA: synthesis, characterization, and antiviral activity. , 2000, Biochemistry.

[48]  C. Broder,et al.  Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages , 1996, Journal of virology.

[49]  R. Pauwels,et al.  Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. , 1995, Journal of medicinal chemistry.

[50]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[51]  N. Yamamoto,et al.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. , 1985, Science.

[52]  E. De Clercq,et al.  Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100 , 1998, Journal of Virology.

[53]  J Desmyter,et al.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. , 1988, Journal of virological methods.

[54]  E. De Clercq,et al.  The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. , 1999, AIDS.

[55]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[56]  J. Blanco,et al.  Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells , 1997, Journal of virology.

[57]  R. Pal,et al.  Effect of Evans blue and trypan blue on syncytia formation and infectivity of human immunodeficiency virus type I and type II in vitro. , 1991, AIDS research and human retroviruses.

[58]  B. Clotet,et al.  Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. , 1999, AIDS.